Evidence map›Paper›PMID 42260731›Full record

ArticlePharmacology research & perspectives2026

AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist.

Monica Patel, Dharshini Ganeshan, Izzy Horgan, Hannah Partington, Michelle Glass

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist.Pharmacology research & perspectives · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Monica PatelDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0003-2686-7246
Dharshini GaneshanDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
Izzy HorganDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
Hannah PartingtonNew Zealand Institute for Public Health and Forensic Science (PHF Science), Auckland, New Zealand.ORCID 0000-0003-4255-0548
Michelle GlassDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-5997-6898

Funding

Investigation of Synthetic Cannabinoid Exposures and Pharmacological ConsequencesR01DA040460 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI RANGAN MAITRA, Yanan Zhang · 2016 to 2026
$4.5M
Division of Health Sciences, University of OtagoNIH HHS R01DA040460
6 · The paper itself

Abstract

Synthetic cannabinoids remain one of the most prominent classes of New Psychoactive Substances (NPS). The introduction of "blanket bans" has only invigorated the development and emergence of novel compounds. Recently, a putative synthetic cannabinoid, AB-MDMSBA, was identified in Australia and New Zealand, with little to no pharmacological data on this compound. This current study, therefore, aimed to determine the potential activity of AB-MDMSBA at the human cannabinoid CB

Indexed as

Cannabinoid Receptor AgonistsCannabinoidsReceptor, Cannabinoid, CB1beta-ArrestinsCyclic AMPHEK293 CellsHumansIndazolesAB-FUBINACAbeta-ArrestinsCannabinoid Receptor AgonistsCannabinoidsCyclic AMPIndazolesReceptor, Cannabinoid, CB1cannabinoid CB1 receptorsynthetic cannabinoid receptor agonisttoxicity

Identifiers

PMID42260731
PMCPMC13246468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.